Stroke

Cardiovascular departments are playing a role in stroke interventions at numerous health systems, working as part of the stroke care team with neurologists, radiology and the emergency department. Stroke first has be be classified as ischemic or hemorrhagic. These have very different care pathways. Ischemic strokes are increasingly being treated with neurological-interventional therapy that includes catheter based mechanical thrombectomy to remove the clot. This is a more aggressive treatment compared to traditional IV administration of tissue plasminogen activator (tPA) thrombolytic therapy to dissolve the clot. Subarachnoid hemorrhage (SAH) and intracerebral hemorrhage (ICH) brain bleeds can also be treated in some cases stent flow diverters and embolization coils.

Abbott’s Amulet LAAO device linked to long-term safety, effectiveness
Researchers explored five-year data from more than 1,800 patients with nonvalvular AFib who underwent LAAO with Abbott's Amulet or Boston Scientific's Watchman 2.5.
Food insecurity increases risk of poor heart health in young adults
Food insecurity—lacking consistent access to the food needed to live an “active, healthy lifestyle”—impacts up to one in eight Americans each year.
Tenecteplase compares favorably to alteplase in new comparison of FDA-approved stroke drugs
Researchers explored data from nearly 80,000 patients, comparing the newest clot-busting stroke drug from Genetech with its predecessor.
FDA approves first new clot-dissolving drug for ischemic stroke in decades
Tenecteplase is a tissue plasminogen activator given to patients through a single five-second intravenous bolus. It is only the second drug of its kind to gain FDA approval, and the first in many years.
FDA announces catheter recall for Johnson & Johnson PFA system due to stroke risk
The recall comes after approximately 3% of patients treated with the device during the early stages of its U.S. rollout experienced a stroke or transient ischemic attack following surgery. The expected stroke rate is closer to 1%, the FDA explained.

Amplatzer Amulet Left Atrial Appendage Occluder (LAAO) from Abbott

Abbott’s Amulet LAAO device linked to long-term safety, effectiveness

Researchers explored five-year data from more than 1,800 patients with nonvalvular AFib who underwent LAAO with Abbott's Amulet or Boston Scientific's Watchman 2.5.

Food insecurity increases risk of poor heart health in young adults

Food insecurity—lacking consistent access to the food needed to live an “active, healthy lifestyle”—impacts up to one in eight Americans each year.

IV hospital room intravenous drip solution

Tenecteplase compares favorably to alteplase in new comparison of FDA-approved stroke drugs

Researchers explored data from nearly 80,000 patients, comparing the newest clot-busting stroke drug from Genetech with its predecessor.

FDA approves first new clot-dissolving drug for ischemic stroke in decades

Tenecteplase is a tissue plasminogen activator given to patients through a single five-second intravenous bolus. It is only the second drug of its kind to gain FDA approval, and the first in many years.

The late-breaking U.S. multicenter admIRE clinical trial at the Heart Rhythm Society 2024 meeting, showed positive data on the long-term safety and effectiveness of the the Biosense Webster Varipulse pulsed field ablation (PFA) system in patients with paroxysmal atrial fibrillation. #HRS #HRS2024 #PFA

FDA announces catheter recall for Johnson & Johnson PFA system due to stroke risk

The recall comes after approximately 3% of patients treated with the device during the early stages of its U.S. rollout experienced a stroke or transient ischemic attack following surgery. The expected stroke rate is closer to 1%, the FDA explained.

Aakriti Gupta, MD, Cedars-Sinai, explains use of cerebral embolic protection devices in TAVR

An updated look at the use of cerebral embolic protection devices during TAVR

Cardiologist Aakriti Gupta, MD, MSc, spoke to Cardiovascular Business about the latest data and trends associated with using cerebral embolic protection devices during TAVR to lower the risk of stroke.

Sotagliflozin the first drug of its kind to limit heart attacks, strokes in high-risk patients

Sotagliflozin, a dual SGLTI and SGLT2 inhibitor, can significantly reduce the risk of adverse cardiovascular events in patients with type 2 diabetes, CKD and additional cardiovascular risk factors, according to a new study of more than 10,000 patients.

Johnson & Johnson MedTech has launched a new next-generation catheter to be used when treating acute ischemic stroke patients. The Cereglide 92 Catheter System includes a 0.92” catheter as well as the company’s Innerglide 9 deliver aid.

Johnson & Johnson MedTech launches new large-bore catheter system for stroke

The next-generation catheter was designed to help clinicians restore blood flow safely and effectively after patients have experienced an acute ischemic stroke.

Around the web

Radiology Business

The impact of Trump tariffs on iodine contrast media costs

GE HealthCare said the price of iodine contrast increased by more than 200% between 2017 to 2023. Will new Chinese tariffs drive costs even higher?

Radiology Business

Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.